Cargando…
Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis
BACKGROUND: Small cell lung cancer (SCLC) is a highly malignant lung cancer with a very poor prognosis. Clinical treatment options for SCLC are still limited, especially for patients who have failed first or second line therapy. Anlotinib is a potentially beneficial new treatment option for SCLC. Th...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951826/ https://www.ncbi.nlm.nih.gov/pubmed/33705427 http://dx.doi.org/10.1371/journal.pone.0247494 |